Correlation between serum tumor necrosis factor alpha levels and clinical severity of tuberculosis

Brazilian Journal of Infectious Diseases

Volumn 12, Issue 3, 2008, Pages 226-233

  de Andrade, Dahir Ramos Jr ^a,b   dos Santos, Sânia Alves ^a   de Castro, Isac ^a   de Andrade, Danir Ramos ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Clinical severity; Cytokines; TNF alpha; Tuberculosis

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BIOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; WEIGHT REDUCTION;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 54349111200     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Kindler V, Sappino A.P., Grau G.E., et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731-40.
2. Cunha R.M.C., Kallas E.G, Rodrigues D.S., et al. Interferon-g and tumour necrosis factor-a production by CD4+ T and CD8 + T lymphocytes in AIDS patients with Tuberculosis. Clin Exper Immunol 1995;140:491-7.
3. Juffermans N.P., Verbon A., van Deventer S.J., et al. Tumor necrosis factor and ýnterleukin-1 inhibitors as markers of disease activity of tuberculosis. Amer J Respir Crit Care Med 1998; 157:1328-31.
4. McDermott M.F. TNF and TNFR biology in health and disease. Cell Molec Biol 2001;47:619-35.
5. Park S.H., Bendelac A. CD1-restricted T-cell responses and microbial infection. Nature 2000;406:788-92.
6. Lewinsohn D.M., Briden A.L., Reed S.G., et al. Mycobacterium tuberculosis-reactive CD8+ T lymphocytes: the relative contribution of classical versus nonclassical HLA restriction. J Immunol 2000; 165:925-30.
7. Serbina N.V., Liu C.C., Scanga C.A., Flynn LL. CD8+ CTL from lungs of Mycobacterium tuberculosis-infected mice express perforin in vivo and lyse infected macrophages. J Immunol 2000;165:353-63.
8. D'Andrea A., Aste-Amezaga M., Valiante N.M., et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993;178:1041-8.
9. Gerosa R, Paganin C., Peritt D., et al. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J Exp Med 1996;183:2559-69.
10. Gerosa F., Nisii C., Righetti S., et al. CD4+ T cell clones producing both interferon-γ and interleukin-10 predominate in bronchoalveolar lavages of active pulmonary tuberculosis patients. Clin Immunol 1999;92:224-34.
11. Seah G.T., Scott G.M., Rook G.A.W. Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J Infect Dis 2000;181:385-9.
12. Steyn A.J.C., Chan J., Mehra V. Recent developments in mycobacterial research. Cur Opin Infect Dis 1999;12:415-24.
13. Bekker LG, Maartens G., Steyn L., Kaplan G. Selective increase in plasma tumor necrosis factor - a and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. J Infect Dis 1998;178:580-4.
14. Silver R.F., Li Q., Ellner J.J. Expression of virulence of Mycobacterium tuberculosis within human monocyles: virulence correlates with intracellular growth and induction of tumor necrosis factor alpha but not with evasion of lymphocyte - dependent monocyte effector functions. Infect Immun 1998;66:1190-9.
15. Dlugovitzky D., Bay M.L, Rateni L, et al. In vitro synthesis of interferon gamma, interleukin 4, transforming growth factor beta, and interleukin Ibeta, by peripheral blood mononuclear cells from tuberculosis patients: relationship with severity of pulmonary involvement. Scand J Immunol 1999;49:210-7.
16. Wang C.H., Liu C.Y., Lin, H.C., et al. Increased exhaled nitric oxide in active pulmonary tuberculosis due to inducible NO synthase upregulation in alveolar macrophages. Europ Resp J 1998; 11: 809-15.
17. McGee Z.A., Clemens C.M. Effect of bacterial products on tumor necrosis factor production: quantitation in biological fluids or tissues. Meth Enzymol 1994;236:23-31.
18. Barnes P.F., Wizel B. Type 1 cytokines and the pathogenesis of tuberculosis. Amer J Respir Crit Care Med 2000;161:1773-4.
19. Ribeiro-Rodrigues R., Resende-Co, T.; Johnson, J.L, et al. Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance. Clin Diagn Lab Immunol 2002;9:818-23.
20. Bossola M., Muscaritoli M., Bellantone R. et al. Serum tumour necrosis factor - alpha levels in cancer patients are discontinuous and correlate with weight loss. Europ J Clin Invest 2000;30:1107-12.
21. Cakir B., Yönem A., Güler S., et al. Relation of leptin and tumor necrosis factor alpha to body weight changes in patients with pulmonary tuberculosis. Horm, Res 1999;52:279-83.
22. Ling P.R., Schwartz J.H., Bristrian B.R. Mechanisms of host wasting induced by administration of cytokines in rats. Amer J Physiol 1997;272(3pt1):E333-9.
23. Tsao T.C., Hong J., Huang C., et al. Increase TNF-α IL-1β and IL-6 levels in the bronchoalveolar lavage fluid with the upregulation of their mRNA in macrophages lavaged from patients with active pulmonary tuberculosis. Tuber Lung Dis 1999;79:279-85.
24. Tsao T.C., Hong, J., Li L.F, et al. Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-1 beta and interleuldn-1 receptor antagonist m BAL fluid of cavitary pulmonary tuberculosis. Chest 2000;117:103-9.
25. Chu C.Q., Field M., Andrew E., et al. Detection of cytokines at the site of tuberculin-induced delayed-type hypersensitivity in man. Clin Exp Immunol 1992;90:522-9.
26. Vankayalapati R., Wizel B., Weis, S.E., et al. Production of interleukin-18 in human tuberculosis. J Infect Dis 2000;182:234-9.
27. Tahhan M., Ugurman F., Gozu A., et al. Tumour necrosis factor-alpha in comparison to adenosine deaminase in tuberculous pleuritis. Respiration 2003;70:270-4.
28. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with Tumor Necrosis Factor antagonists. Clin Infect Dis 2004;38:1261-5.
29. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with Tumor Necrosis Factor antagonists. Arthr Rheum 2005;52:1766-72.
30. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science 1998;281:1305-8.
31. Krammer P.H. CD95's deadly mission in the immune system. Nature 2000;407:789-95.
32. Doi T.S., Marino M.W., Takahashi T., et al. Absence of tumor necrosis factor rescues Re1A-deficient mice from embryonic lethality. Proc Natl Acad Sci 1999;96:2994-9.
33. Ciaramella. A., Cavone A., Santucci M.B., et al. Proinflammatory cytokines in the course of Mycobacterium tuberculosis-induced apoptosis in monocytes/macrophages. J Infect Dis 2002;186:1277-82.
34. Keane J., Balcewicz-Sablinska M.K., Remold H.G, et al. Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect Immun 1997;65:298-304.
35. Watson V.E., Hill L.L., Owen-Schaub L.B., et al. Apoptosis in Mycobacterium tuberculosis infection in mice exhibiting varied immunopathology. J Path 2000;190:211-20.